Biotech major Biocon drug Hulio’s commercialisation rights have been extended to global markets from Europe, said the biotech major on Wednesday.
“Under the terms of global partnership with Mylan for monoclonal antibodies (like Hulio), we retain our economic interest in the expanded in-licensing arrangement to a share of profits from global markets, said the city-based company in a statement here.
Biocon’s drug partner Mylan N.V. is a global generic and specialty pharmaceuticals firm registered in the Netherlands, with offices in Britain and a global research centre in the US.
Hulio, which is used to treat ulcerative colitis in adults, has been in-licensed to Biocon by Mylan on approval from the Japan-based Fujifilm Kyowa Kirin Biologics.
Mylan launched Hulio in Europe in October 2018 after the European Commission approved it in September 2018.
“We are committed to enable patient access to affordable biosimilars and the partnership accelerates that process,” said Biocon spokesperson in the statement.